Table 1 Baseline characteristics of patients
From: Lidocaine for systemic sclerosis: a double-blind randomized clinical trial
Placebo group (n = 12) | Lidocaine group (n = 12) | |
|---|---|---|
Gender, n (%) | ||
Female | 10 (83.4%) | 10 (83.4%) |
Male | 2 (16.6%) | 2 (16.6%) |
Age, mean years ± SD | 41.2 ± 11.1 | 40.8 ± 7.9 |
Type of involvement, n (%) | ||
Limited | 4 (33.3%) | 3 (25%) |
Diffuse | 8 (66.6%) | 9 (75%) |
Duration of the disease since manifestation of first symptoms, mean months (± SD | 39.8 ± 15.9 | 41.5 ± 13.7 |
Use of corticosteroids, n (%) | 8 (66.6%) | 8 (66.6%) |
Modified Rodnan skin score, mean ± SD | 19.41 | 17.12 |
Capillary dropout, mean ± SD | 1.8 ± 1.0 | 1.3 ± 1.1 |
Enlarged capillary loops, mean ± SD | 4.04 | 2.90 |
Average amplitude of peristaltic contractions, mean mmHg (± SD | 48.2 ± 38.8 | 47.6 ± 49.2 |
Lower esophageal sphincter pressure (at average airway pressure), mmHg mean ± SD | 14.3 ± 6.9 | 13.6 ± 10.1 |
Health assessment questionnaire, mean ± SD | 0.6 ± 0.4 | 0.8 ± 0.5 |